Evotec

Cord Dohrmann will step down as chief scientific officer and member of the executive board of EVOTEC on 30 September; the decision was mutual. Dohrmann has held the position since 2010. A search for his successor is underway; the EVOTEC share was slightly firmer in XETRA trading. » Więcej na finanzen.net

The Evotec share rose to €3.098 and led the SDAX higher, driven by an optimistic outlook at a conference. CFO Claire Hinshelwood said business indicators were developing “in the right direction” and are likely to translate into future revenues. The cost-saving programme Horizon is running as planned and the pipeline of deals is robust. » Więcej na finanzen.net

Just‑Evotec Biologics launches a Phase‑I study for the orthopox antibody cocktail JST‑018 under a U.S. Department of Defense program; together with a previous contract the potential order volume is up to USD 123.9 million. The project confirms the functionality of Evotec’s continuous‑manufacturing platform through production of clinical material and strengthens the high‑margin biologics division. Chart‑wise, Evotec’s share remains in an intact downtrend and is trading near its 52‑week low, so investors will still need patience and risk tolerance until operational successes are reflected in the group’s financials. » Więcej na finanzen.net